Neoplasms

Mouth and Tooth Diseases

Ear, Nose, and Throat Diseases

All Conditions

Digestive System Diseases

Blood and Lymph Conditions

Immune System Diseases

Infections

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Symptoms and General Pathology

Rare Diseases

Nasopharyngeal Carcinoma

Stomach Neoplasms

Sarcoma

Lymphoma

Acquired Immunodeficiency Syndrome

HIV Infections

Lymphoproliferative Disorders

Hodgkin Disease

Sarcoma, Kaposi

Lymphoma, AIDS-Related

Lymphoma, Primary Effusion

Nasopharyngeal Neoplasms

Carcinoma

Neoplasms by Histologic Type

Lymphatic Diseases

Immunoproliferative Disorders

Neoplasms, Connective and Soft Tissue

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Stomach Diseases

Communicable Diseases

Herpesviridae Infections

Virus Diseases

DNA Virus Infections

Neoplasms, Vascular Tissue

Pharyngeal Neoplasms

Otorhinolaryngologic Neoplasms

Head and Neck Neoplasms

Nasopharyngeal Diseases

Pharyngeal Diseases

Stomatognathic Diseases

Otorhinolaryngologic Diseases

Neoplasms, Glandular and Epithelial

Stomach Cancer

Soft Tissue Sarcoma

Lymphosarcoma

Hodgkin Lymphoma

Kaposi Sarcoma

Lymphoma AIDS Related

Primary Effusion Lymphoma

Anti-Infective Agents

All Drugs and Chemicals

Fialuridine

Antiviral Agents

Enzyme Inhibitors

GROUP B 1-3 days after any chemotherapy that may activate viral TK, 4 mCi of I-FIAU are administered, followed 2 - 4 hours later by FIAU-PET-CT-4.

GROUP A 1-3 days after any chemotherapy that may activate viral TK, 2 mCi of I-FIAU are administered, followed 2 - 4 hours later by FIAU-PET-CT-2.

1-3 days after chemotherapy, subject get I-FIAU 2 mCi, then have FIAU-PET-CT done 2 - 4 hours after I-FIAU

FIAU-PET-CT-2

1-3 days after any chemotherapy that may activate viral TK, 4 mCi, rather than 2 mCi, of I-FIAU are administered, followed 2 - 4 hours later by FIAU-PET-CT

FIAU-PET-CT-4

Richard Ambinder, M.D.

This research is being done to determine whether viral thymidine kinase (TK) expression in Epstein-Barr virus (EBV) and Kaposi's sarcoma herpesvirus (KSHV) virus-associated tumors is sufficient to image.

EBV and KSHV are associated with a variety of malignancies including some lymphomas, carcinomas and other malignancies. We anticipate that viral TK expression will differ among tumor types and will be adjusted with standard chemotherapies and some investigational agents. This exploratory study is aimed in part at evaluating whether standard regimens or investigational regimens might bring about sufficient activation of the EBV-TK or KSHV-TK in tumors to be therapeutically useful if used in conjunction with FIAU as a radiopharmaceutical.

124I-FIAU Imaging in EBV and KSHV Associated Cancers

Study of Imaging of Viral Thymidine Kinase Activity in EBV-Associated and KSHV-Associated Malignancies

National Cancer Institute (NCI)

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
124I-FIAU Imaging in EBV and KSHV Associated Cancers	NCT00982449	Hodgkin Lymphom... Non Hodgkin Lym... Kaposi's Sarcom... Gastric Cancer Nasopharyngeal ...	FIAU-PET-CT-2 FIAU-PET-CT-4	18 Years - 75 Years	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
124I-FIAU Imaging in EBV and KSHV Associated Cancers	NCT00982449	Hodgkin Lymphom... Non Hodgkin Lym... Kaposi's Sarcom... Gastric Cancer Nasopharyngeal ...	FIAU-PET-CT-2 FIAU-PET-CT-4	18 Years - 75 Years	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Spots Global Cancer Trial Database for ebv+ malignancies